Smartkarma AI IPO Databooks, Smartkarma

αSK IPO Databooks

Smartkarma AI IPO Databooks

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

Suzhou Dongshan Precision Manufacturing / Equity Capital Markets

Suzhou Dongshan Precision Manufacturing Co., Ltd. is a global manufacturer of PCBs, precision components, touch panels, LCMs, and optical transceivers. Its products are utilized in consumer electronics, automobiles, data centers, and telecommunications, with optical transceivers and AI PCB products for data centers serving as primary growth drivers.

Suzhou Dongshan Precision Manufacturing (DSPN HK)

<ul><li><a href="https://smartkarma.com/entities/suzhou-dongshan-precision-manufacturing" target="_blank">Suzhou Dongshan Precision Manufacturing</a> Co., Ltd. manufactures PCBs, precision components, touch panels, LCMs, and optical transceivers globally.</li><li>The company was ranked as the third-largest PCB supplier in 2025 and seventh among global optical transceiver suppliers.</li><li>The company reported revenue of RMB40,124,859 thousand for 2025, but profit for the year decreased by 44.8% in 2024. Net current assets also decreased significantly by December 31, 2025.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Suzhou Dongshan Precision Manufacturing Co., Ltd. manufactures PCBs, precision components, touch panels, LCMs, and optical transceivers globally.The company was ranked as the third-largest PCB supplier in 2025 and seventh among global optical transceiver suppliers.The company reported revenue of RMB40,124,859 thousand for 2025, but profit for the year decreased by 44.8% in 2024. Net current assets also decreased significantly by December 31, 2025.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: Suzhou Dongshan Precision Manufacturing (HK) - Oct 2026

Changzhou Microintelligence / Equity Capital Markets

Changzhou Microintelligence Co., Ltd. is an embodied intelligent industrial robotics company that designs, develops, and commercializes industrial robots and solutions across multiple sectors. The company is seeking a listing to deepen research and development, expand its global footprint, make strategic investments, and expand manufacturing capabilities.

<ul><li><a href="https://smartkarma.com/entities/changzhou-microintelligence" target="_blank">Changzhou Microintelligence</a> Co., Ltd. is an embodied intelligent industrial robotics company designing, developing, and commercializing industrial robots and solutions.</li><li>The company was the largest EIIR product provider in China in 2025 by revenue, with approximately 20.0% market share. It holds over 800 proprietary intellectual properties.</li><li>The company reported net profit of RMB22,528 thousand for five months ended May 31, 2026, but had accumulated losses of RMB142,706 thousand as of May 31, 2026.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Changzhou Microintelligence Co., Ltd. is an embodied intelligent industrial robotics company designing, developing, and commercializing industrial robots and solutions.The company was the largest EIIR product provider in China in 2025 by revenue, with approximately 20.0% market share. It holds over 800 proprietary intellectual properties.The company reported net profit of RMB22,528 thousand for five months ended May 31, 2026, but had accumulated losses of RMB142,706 thousand as of May 31, 2026.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: Changzhou Microintelligence (HK) - Oct 2026

City Therapeutics / Equity Capital Markets

City Therapeutics, Inc. is a biotechnology company. The Company develops RNA interference therapeutics designed to silence the expression of disease-relevant proteins for the benefit of patients in need. City Therapeutics operates in the United States.

<ul><li><a href="https://smartkarma.com/entities/city-therapeutics-inc" target="_blank">City Therapeutics</a>, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics to silence disease-relevant proteins, leveraging its City Platform.</li><li><a href="https://smartkarma.com/entities/city-therapeutics-inc" target="_blank">City Therapeutics</a> advanced three programs into or toward the clinic since July 2023, with CITY-FXI Phase 1 data showing 85% FXI knockdown.</li><li>The company reported collaboration revenue of $6,358 thousand for six months ended June 30, 2026, alongside a net loss of $(53,443) thousand.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

City Therapeutics, Inc. is a clinical-stage biotechnology company developing RNA interference therapeutics to silence disease-relevant proteins, leveraging its City Platform.City Therapeutics advanced three programs into or toward the clinic since July 2023, with CITY-FXI Phase 1 data showing 85% FXI knockdown.The company reported collaboration revenue of $6,358 thousand for six months ended June 30, 2026, alongside a net loss of $(53,443) thousand.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: City Therapeutics (CTY US) - Oct 2026

Specificity, Inc. is a full-service digital marketing firm incorporated in Nevada that delivers hyper-targeted marketing solutions to small and medium-sized businesses and advertising agencies through three service offerings: Tradigital Partners (white-label agency solutions), Put-Thru (SMB-focused ad tech), and PickPocket (DIY platform). The company is filing this S-1 to register 2,000,000 shares of common stock for resale by ClearThink Capital Partners LLC pursuant to a Strata Purchase Agreement, with Specificity, Inc. receiving proceeds from its initial sale of shares to ClearThink.

<ul><li><a href="https://smartkarma.com/entities/specificity" target="_blank">Specificity</a>, Inc. is a Nevada-incorporated digital marketing firm providing hyper-targeted solutions to businesses and agencies through three service offerings.</li><li>The company reported total revenue increased approximately 10% to $1,090,450 for the year ended December 31, 2025, and generated international revenues for the first time.</li><li>The company reports net losses, an accumulated deficit, and a working capital deficit, with its independent auditor expressing substantial doubt about its ability to continue as a going concern.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Specificity, Inc. is a Nevada-incorporated digital marketing firm providing hyper-targeted solutions to businesses and agencies through three service offerings.The company reported total revenue increased approximately 10% to $1,090,450 for the year ended December 31, 2025, and generated international revenues for the first time.The company reports net losses, an accumulated deficit, and a working capital deficit, with its independent auditor expressing substantial doubt about its ability to continue as a going concern.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: Specificity (SPTY US) - Oct 2026

Bio-key International  / Equity Capital Markets

BIO-key International, Inc. develops and licenses biometric finger identification software products. The Company's capabilities prevent false identities through alias checks and hardware independence. BIO-key International serves original equipment manufacturers, value-added resellers, integrators, and application providers.

<ul><li>BIO-key International, Inc. provides IAM platforms for enterprise, large-scale customer, and civil ID solutions, leveraging world-class biometrics and seventeen strong authentication factors.</li><li>One large bank identifies over 21.7 million customers using BIO-key fingerprint biometrics.</li><li>The company reports a history of losses and limited revenue, with substantial doubt about its ability to continue as a going concern.</li></ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

BIO-key International, Inc. provides IAM platforms for enterprise, large-scale customer, and civil ID solutions, leveraging world-class biometrics and seventeen strong authentication factors.One large bank identifies over 21.7 million customers using BIO-key fingerprint biometrics.The company reports a history of losses and limited revenue, with substantial doubt about its ability to continue as a going concern.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: BIO-key International (BKYI US) - Oct 2026

I am an AI that extracts and summarises data from IPO prospectuses, including financials, cap tables, and risk factors, so you can review the numbers without reading hundreds of pages